|
Dishman Pharmaceuticals And Chemicals (Angel) In-line performance during the quarter |
| Date | Rating | Target Price | Recommendation Price | Broker house | | 1 Aug 2011 | buy | 133 | 87 | Angel Report | |
|
Dishman Pharmaceuticals And Chemicals (Emkay) High on Hopes – Maintain Accumulate |
|
Results Highlights – Base business disappoints;Future growth drivers | Date | Rating | Target Price | Recommendation Price | Broker house | | 28 Jul 2011 | accumulate | 125 | 89 | Emkay Report | |
|
Dishman Pharmaceuticals And Chemicals (Citi) Carbogen Disappoints Again |
|
1Q a Mixed Bag;Steady Top-line Growth;Recurring PAT lower;FY12 Guidance Maintained | Date | Rating | Target Price | Recommendation Price | Broker house | | 28 Jul 2011 | buy | 115 | 89 | Citi Report | |
|
Dishman Pharmaceuticals And Chemicals (Citi) Worst Appears Behind; Pace of Recovery Hazy |
|
Road to Recovery;Revenues Set to Recover;Margins to Improve off a Low Base;Revising Estimates | Date | Rating | Target Price | Recommendation Price | Broker house | | 24 Jun 2011 | buy | 115 (from 265) | 87 | Citi Report | |
|
dishman pharmaceuticals (Angel) Positive surprise during the quarter |
|
dishman pharma (Emkay) Subdued performance to continue |
Q4FY11 was above our expectations with a) Revenues at Rs3.44 bn (up 39% YoY), EBIDTA at Rs555 mn (up 12% YoY) and APAT at Rs214 mn (up 18% YoY)
| Date |
Rating |
Target Price |
Recommendation Price |
Broker house |
| 26 May 2011 |
accumulate |
125 |
96 |
Emkay Report |
Yahoo Link+NSE Link+Reuters Link+Reuters India Link+Google Link+DSR Search
Reports.DesiStockResearch.com |
|
dishman pharma (emkay) Demand Recovery Underway |
Dishman's Indian CRAMS business to see some respite as supplies to European customer set to begin from Q1FY12 leading to higher operating leverage
| Date |
Rating |
Target Price |
Recommendation Price |
Broker house |
| 11 Apr 2011 |
accumulate (from hold) |
125 |
102 |
emkay Report |
Yahoo Link+NSE Link+Reuters Link+Reuters India Link+Google Link+DSR Search
Reports.DesiStockResearch.com |
|
dishman pharma (Angel) Poor performance across key segments |
|
dishnam pharma (ICICIsec) Cintinue to disappoint |
|
dishman pharma (emkay) Another quarter of dismal performance |
